Clarithromycin

Cat-Scratch Disease, Sinusitis, Whooping Cough + 14 more

Treatment

21 FDA approvals

20 Active Studies for Clarithromycin

What is Clarithromycin

Clarithromycin

The Generic name of this drug

Treatment Summary

Clarithromycin is an antibiotic derived from erythromycin. It works by inhibiting the production of proteins in bacteria, which prevents them from multiplying. Depending on the concentration of the drug, it can either stop the bacteria from growing or kill them.

Biaxin

is the brand name

image of different drug pills on a surface

Clarithromycin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Biaxin

Clarithromycin

1991

187

Approved as Treatment by the FDA

Clarithromycin, also known as Biaxin, is approved by the FDA for 21 uses which include Acute maxillary sinusitis and Bacterial Infections .

Acute maxillary sinusitis

Bacterial Infections

Otitis Media (OM)

Mycobacterial Infections

uncomplicated skin and subcutaneous tissue bacterial infections

prophylaxis of Mycobacterial infection

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Tonsillitis streptococcal

Streptococcal Pharyngitis

Bronchitis, Chronic

Urinary Tract Infection (UTI)

HIV

Otitis

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Mycobacterium Infections

Sinusitis

Community Acquired Pneumonia (CAP)

Bacterial Infections

Tuberculosis

Tonsillitis

Effectiveness

How Clarithromycin Affects Patients

Clarithromycin is a type of antibiotic used to treat a range of bacteria, including many common types such as Staphylococcus aureus, Haemophilus influenzae, Mycoplasma, and Chlamydia. It has been found to be as effective or more effective than erythromycin against certain bacteria. Clarithromycin usually stops bacteria from reproducing, but can sometimes kill them.

How Clarithromycin works in the body

Clarithromycin works by entering bacteria cells and binding to a part of their ribosomes, which are responsible for making proteins. This binding blocks the bacteria's ability to make proteins, preventing it from reproducing and causing infection. Clarithromycin also stops enzymes that break down medicine in the liver, making it more effective.

When to interrupt dosage

The recommended dosage of Clarithromycin is contingent upon the determined condition, for instance Mycobacterium Infections, Lyme Disease and Bacterial Infections. The amount may vary as per the administration technique (e.g. Powder, for suspension or Capsule; Kit; Tablet) featured in the table below.

Condition

Dosage

Administration

Mycobacterium Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tuberculosis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Duodenal Ulcer

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

HIV

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bronchitis, Chronic

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Community Acquired Pneumonia (CAP)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Streptococcal Pharyngitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Cat-Scratch Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Sinusitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Whooping Cough

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Lyme Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Urinary Tract Infection (UTI)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tonsillitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Otitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Warnings

Clarithromycin Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

There are 20 known major drug interactions with Clarithromycin.

Common Clarithromycin Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Clarithromycin.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Clarithromycin.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Clarithromycin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Clarithromycin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Clarithromycin.

Clarithromycin Toxicity & Overdose Risk

Symptoms of clarithromycin toxicity include diarrhea, nausea, bad taste, indigestion, stomach pain, and temporary hearing loss. In some cases, colitis, allergic reactions (from hives to anaphylaxis), liver damage, and tooth discoloration have been reported. Animal studies have also linked clarithromycin to fetal abnormalities such as heart defects, cleft palate and slow growth. Additionally, this drug may cause a prolonged QT interval.

image of a doctor in a lab doing drug, clinical research

Clarithromycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Clarithromycin?

160 active clinical trials are currently exploring the potential of Clarithromycin to provide relief for Pertussis, HIV and Urinary Tract Infection (UTI).

Condition

Clinical Trials

Trial Phases

Mycobacterium Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Streptococcal Pharyngitis

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Otitis

0 Actively Recruiting

Cat-Scratch Disease

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Bacterial Endocarditis

1 Actively Recruiting

Not Applicable

Duodenal Ulcer

0 Actively Recruiting

Bacterial Endocarditis

0 Actively Recruiting

Tuberculosis

0 Actively Recruiting

Lyme Disease

3 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable

Clarithromycin Reviews: What are patients saying about Clarithromycin?

4.7

Patient Review

7/25/2022

Clarithromycin for infection caused by bacteria

I was in a lot of pain from an untreated bacterial infection, and these tablets were worth their weight in gold to me. I don't care about the side effects; they made me better. If you're bothered about the side effects, then you must not have been in as much pain as I was. Get a life—thank goodness you're alive and these tablets made you better instead of complaining about the side effects!

3.3

Patient Review

7/19/2022

Clarithromycin for Acute Infection of the Nose, Throat or Sinus

I got tonsillitis, then my doctor recommended this Clarithromycine antibiotic. On the first day, the pain in my tonsils lessened. However, I didn't like its side effect; whenever I ate and took the medicine, I felt stomach pain and vomitied every two hours.

2.3

Patient Review

7/3/2022

Clarithromycin for Infection of the Middle Ear caused by Streptococcus

After only three days of taking this antibiotic, I experienced a range of awful side effects, including but not limited to: jitters, watery diarrhea, nausea, fatigue, headache and brain fog. Never have I felt this bad before; I had to stop taking the medication and will never take it again. It's unbelievable that this is on the market.

2.3

Patient Review

6/15/2022

Clarithromycin for Middle Ear Infection

I was given this medication because of an ear infection after having the flu. On the first day, I had severe stomach pain for around 20 minutes. However, what really bothered me from the second day onward was the bitter taste in my mouth that didn't go away for more than 8 hours after taking the medication. Today is my third day, and the bitter saliva is still bothering me.

2.3

Patient Review

10/11/2022

Clarithromycin for infection caused by bacteria

I found the recommended dosage of this drug to be far too much for my system. I had severe reactions including joint and muscle pain, nausea, and insomnia. If you've ever had a reaction to antibiotics in the past, I would recommend avoiding this medication entirely.

2.3

Patient Review

4/16/2022

Clarithromycin for Acute Infection of the Nose, Throat or Sinus

I never want to take this again. It sent my anxiety levels through the roof and I would rather be in pain than deal with the side effects.

1.3

Patient Review

1/9/2022

Clarithromycin for Acute Maxillary Sinus H. Influenzae Bacteria Infection

I unfortunately experienced a range of adverse effects from taking this medication. I would advise against it based on my personal experience.

1.3

Patient Review

4/25/2022

Clarithromycin for Middle Ear Infection

The side effects of Klacid were so bad that I couldn't even finish the course of antibiotics. I experienced insomnia, restlessness, and awful abdominal cramps and nausea. I would never use this medication again.

1

Patient Review

11/10/2022

Clarithromycin for infection caused by bacteria

I had some nasty side effects after only taking this twice. I wouldn't recommend it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about clarithromycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is clarithromycin stronger than amoxicillin?

"Clarithromycin seems to work as well as amoxicillin/clavulanate against acute maxillary sinusitis, and it may cause fewer problems with upset stomach."

Answered by AI

What are the most common side effects of clarithromycin?

"Some potential side effects of this medication include diarrhea, nausea, vomiting, stomach pain, heartburn, gas, a change in taste, and headache."

Answered by AI

Is clarithromycin and amoxicillin the same?

"This product contains two different types of antibiotics: amoxicillin, which is a penicillin-type antibiotic, and clarithromycin, which is a macrolide-type antibiotic. These antibiotics work by stopping the growth of bacteria, and they are effective against only bacterial infections."

Answered by AI

What is clarithromycin antibiotic used for?

"This drug is used to treat bacterial infections by killing the bacteria. It is also used in tandem with other drugs to treat ulcers in the duodenum, which are caused by the bacteria H. pylori. Additionally, this medication is taken to prevent and treat infection by the Mycobacterium avium complex."

Answered by AI

Clinical Trials for Clarithromycin

Image of New Jersey Community Research Initiative in Newark, United States.

Treatment for HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Have you considered Clarithromycin clinical trials?

We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Clarithromycin clinical trials?

We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.
Go to Trials

Have you considered Clarithromycin clinical trials?

We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.
Go to Trials